Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph I Clark

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Cancer Medicine|April 1, 2025
A Prospective, Multicenter Analysis of Recurrence-Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31-GEPJ Michael Guenther, Andrew Ward, Brian J Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancerKim Margolin, Michael B Atkins, Janice P Dutcher, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group studyJoseph I Clark, Jessica Mehrabi, Jeffrey A Sosman, et al.
Cancer Research|September 17, 2016
Ccl22 Diverts T Regulatory Cells and Controls the Growth of MelanomaJared Klarquist, Kristen Tobin, Peyman Farhangi Oskuei, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|February 5, 2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2Joseph I Clark, Brendan Curti, Elizabeth J Davis, et al.
The Lancet. Oncology|March 30, 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialKim Margolin, Marc S Ernstoff, Omid Hamid, et al.
Journal for Immunotherapy of Cancer|December 20, 2017
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM<sup>SM</sup> registryBrendan Curti, Gregory A Daniels, David F McDermott, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|July 16, 2021
Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary PerspectiveAsser M Abou Elkassem, Simon S Lo, Andrew J Gunn, et al.
Journal for Immunotherapy of Cancer|July 29, 2018
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanomaJoseph I Clark, Jatinder Singh, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanomaJeffrey A Sosman, Carole Carrillo, Walter J Urba, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Cancer Medicine|April 1, 2025
A Prospective, Multicenter Analysis of Recurrence-Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31-GEPJ Michael Guenther, Andrew Ward, Brian J Martin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancerKim Margolin, Michael B Atkins, Janice P Dutcher, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group studyJoseph I Clark, Jessica Mehrabi, Jeffrey A Sosman, et al.
Cancer Research|September 17, 2016
Ccl22 Diverts T Regulatory Cells and Controls the Growth of MelanomaJared Klarquist, Kristen Tobin, Peyman Farhangi Oskuei, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|February 5, 2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2Joseph I Clark, Brendan Curti, Elizabeth J Davis, et al.
The Lancet. Oncology|March 30, 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialKim Margolin, Marc S Ernstoff, Omid Hamid, et al.
Journal for Immunotherapy of Cancer|December 20, 2017
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM<sup>SM</sup> registryBrendan Curti, Gregory A Daniels, David F McDermott, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|July 16, 2021
Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary PerspectiveAsser M Abou Elkassem, Simon S Lo, Andrew J Gunn, et al.
Journal for Immunotherapy of Cancer|July 29, 2018
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanomaJoseph I Clark, Jatinder Singh, Marc S Ernstoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2008
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanomaJeffrey A Sosman, Carole Carrillo, Walter J Urba, et al.
Pageof 7